Previous 10 | Next 10 |
2024-06-04 14:07:57 ET Summary Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the trea...
Annexon, Inc. (NASDAQ: ANNX) is one today's most active stocks by volume. So far today, approximately 36.48M shares of Annexon, Inc. have been exchanged, as compared to an average 30-day volume of 1.44M shares. Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops t...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 115.1% to $0.5667 on volume of 77,631,052 shares MicroAlgo Inc. (MLGO) rose 284.0% to $5.99 on volume of 40,752,997 shares Crown Electrokinetics Corp. (CRKN) fell 13.8% to $0.1016 on volume of 28,247,104 sha...
2024-06-04 07:35:40 ET More on Annexon Biosciences Annexon: Unforced Error Sullies Prospects Biggest stock movers today: GME, HQY, and more Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Fin...
Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscl...
2024-06-04 05:23:18 ET More on related stocks: HealthEquity, Inc. (HQY) Q1 2025 Earnings Call Transcript BARK, Inc. (BARK) Q4 2024 Earnings Call Transcript GameStop Stock: Disconnected From Fundamentals GameStop shares leap 21%; ‘Roaring Kitty’ ...
BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call a...
2024-05-17 17:05:06 ET Gainers: Stronghold Digital Mining ( SDIG ) +7% . New York Mortgage Trust ( NYMT ) +3% . Outbrain ( OB ) +3% . Aquestive Therapeutics ( AQST ) +2% . Airship AI Holdings ( AISP ) +2% . Losers: ...
2024-05-13 08:51:29 ET More on Annexon Biosciences Annexon: Unforced Error Sullies Prospects Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Financial information for Annexon Biosciences Re...
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vi...
News, Short Squeeze, Breakout and More Instantly...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...
2024-06-17 17:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...